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Abstract: Monoclonal antibodies, engineered antibodies, and antibody fragments have become
important biological therapeutic platforms. The IgG format with bivalent binding sites has a modular
structure with different biological roles, i.e., effector and binding functions, in different domains.
We demonstrated the reconstruction of an IgG-like domain structure in vitro by protein ligation using
protein trans-splicing. We produced various binding domains to replace the binding domain of IgG
from Escherichia coli and the Fc domain of human IgG from Brevibacillus choshinensis as split-intein
fusions. We showed that in vitro protein ligation could produce various Fc-fusions at the N-terminus
in vitro from the independently produced domains from different organisms. We thus propose an
off-the-shelf approach for the combinatorial production of Fc fusions in vitro with several distinct
binding domains, particularly from naturally occurring binding domains. Antiviral lectins from
algae are known to inhibit virus entry of HIV and SARS coronavirus. We demonstrated that a lectin
could be fused with the Fc-domain in vitro by protein ligation, producing an IgG-like molecule as
a “lectibody”. Such an Fc-fusion could be produced in vitro by this approach, which could be an
attractive method for developing potential therapeutic agents against rapidly emerging infectious
diseases like SARS coronavirus without any genetic fusion and expression optimization.
Keywords: protein trans-splicing; split intein; immunoglobulin G; lectin; protein ligation; Fc;
scytovirin; segmental isotopic labeling; lectibody
1. Introduction
Immunoglobulin G (IgG) is a multidomain protein that consists of four polypeptide chains.
Two identical heavy chains and two identical light chains form a Y-shaped molecule connected by
disulfide bonds (Figure 1a). While the heavy chain is composed of four structural domains called
immunoglobulin domains (VH, CH1, CH2, and CH3), the light chain has two immunoglobulin domains
(VL and CL) (Figure 1a) [1]. Variable domains VH and VL constitute an antigen-binding region,
bearing two binding sites per IgG. The enormous diversity of the variable domains plays an essential
role in recognizing specific antigens, such as pathogens and foreign molecules in immunity [1].
Constant domains CH2 and CH3 of the two heavy chains construct the Fc domain, which mediates
various effector functions such as antibody-dependent, cell-mediated cytotoxicity (ADCC) and the
activation of complement pathways in immunity. Thus, domain structures of antibodies can be
dissected based on their functional roles. Antibodies from camelids (like camel and llama) lack light
chains, and are therefore termed as heavy-chain antibodies (Figure 1b) [2]. Antigen-binding regions of
the heavy-chain antibodies contain only one immunoglobulin fold termed VHH. The VHH domain
Int. J. Mol. Sci. 2020, 21, 4011; doi:10.3390/ijms21114011 www.mdpi.com/journal/ijms
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replaces the functional role of the variable domains VH and VL in conventional immunoglobulins [2].
The smaller size of VHH provides several advantages, such as simple production and engineering [2].
The VHH domain has been widely used as a standalone agent for biotechnological applications [3,4].
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was adapted from [5]. 
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functions [3,4]. Since the therapeutic efficacy of ADCC by antibodies is mitigated by the fact that not 
all immune cells express antibody receptors, bispecific antibodies have been artificially engineered 
to simultaneously bind to two different types of antigens (Figure 1c) [7]. All IgGs, heavy-chain 
antibodies, and bispecific antibodies commonly contain an Fc domain with some sequence variation, 
while the binding sites are unique to individual formats and antigens. mAbs, Fc fusion proteins, and 
bispecific antibodies are usually produced from a single cell line for each BsAb, mAb, and Fc fusion 
by making stable cell lines to produce the genetically engineered proteins, despite the likely presence 
of the Fc domain among these proteins [8]. Whereas a binding domain such as VHH can be obtained 
by in vitro selection with directed evolution [9], the production of each new mAb from a mammalian 
cell line can be labor-intensive and time-consuming, especially for bispecific antibodies requiring four 
separate constructs (encoding each of the four polypeptide chains for the production of BsAbs) to be 
engineered [10]. 
We aimed to develop an efficient method to produce diverse N-terminal fusion proteins of the 
Fc domain in vitro from dissected domains by protein trans-splicing (Figure 1d,e). Protein splicing is 
Figure 1. Domain structures of immunoglobulin G (IgG) and IgG variants. (a) Domains in IgG with
their functional roles. (b) Domain structure of a heavy-chain antibody. (c) Domain structure of an
engineered bispecific antibody showing each unique chain highlighted in different colors. Dissection of
immunoglobulin G (IgG). (d) IgG can be split into the Fab region, which contains an antigen-binding
site, and the effector domain Fc at two positions in the hinge region. (e) Reconstitution of IgG-like
molecules by protein ligation using protein trans-splicing (PTS) with a split intein. The figure was
adapted from [5].
Monoclonal antibodies such as IgG have increasingly become indispensable biological therapeutic
drugs for cancer and autoimmune diseases, with currently more than 70 ntibody drugs on the
market [6]. Because of their therapeutic success, antibodies represent the fastest growing sector in the
pharmaceutical industry. Therapeutic antibodies typically comprise intact monoclonal IgG molecules
and IgG derivatives [6]. Additionally, antibody fragments have been fused with various functional
moieties, including enzymes, toxins, radionuclides, and viruses, for new therapeutic functions [3,4].
Since the therapeutic efficacy of ADCC by antibodies is mitigated by the fact that not all immune cells
express antibody receptors, bispecific antibodies have been artificially engineered to simultaneously
bind to two different types of antigens (Figure 1c) [7]. All IgGs, heavy-chain antibodies, and bispecific
antibodies commonly contain an Fc domain with some sequence variation, while the binding sites are
unique to individual format and antigens. mAbs, Fc fusion proteins, and bispecific antibodies are
usually produced from a single c ll lin for each BsAb, mAb, and Fc fusion by making stable cell lines to
produce the genetically engineered proteins, despite the likely presence of the Fc domain among these
proteins [8]. Whereas a binding domain such as VHH can be obtained by in vitro selection with directed
evolution [9], the production of each new mAb from a mammalian cell line can be labor-intensive and
time-consuming, especially for bispecific antibodies requiring four separate constructs (encoding each
of the four polypeptide chains for the production of BsAbs) to be engineered [10].
We aimed to develop an efficient method to produce diverse N-terminal fusion proteins of the
Fc domain in vitro from dissected domains by protein trans-splicing (Figure 1d,e). Protein splicing
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is an autocatalytic selfexcision process catalyzed by intein and concomitantly ligating the flanking
protein sequences (exteins), catalyzed by an intein (Figure 2a) [11–13]. Canonical inteins contain a
homing endonuclease (EN) domain. Inteins lacking EN domains are also found in nature and called
mini-inteins (Figure 2b) [12]. Split inteins can catalyze bimolecular protein splicing, namely protein
splicing in trans (Figure 2b) [12]. Since protein trans-splicing (PTS) was established as a protein-ligation
tool of foreign protein sequences with a peptide bond, it has become an essential protein engineering
tool (Figure 2d) [14,15]. The split fragments of an intein are termed N-intein (IntN) and C-intein
(IntC) for N-terminal and C-terminal fragments, respectively [13,14]. Many artificially and naturally
split inteins have been developed and characterized for in vitro protein ligation (Figure 2c) [14,16,17].
In vitro protein ligation of Fc domain with diverse binding domains could circumvent the fusion of
different genes on the DNA level with an identical Fc gene, facilitating in vitro production of Fc fusions
with various binding capabilities using an off-the-shelf approach (Figures 1e and 3) [18,19].
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Figure 2. Protein splicing in cis and trans. (a) Protein splicing in cis. An internal protein (Intein, Int)
is spliced out from a precursor protein, concomitantly ligating the two flanking proteins (N-extein
and C-extein). ExN and ExC indicate N-extein and C-extein, respectively. (b) Canonical intein with
homing endonuclease domain (EN), Mini-intein without EN, and split intein. (c) A cartoon model of
NpuDnaE intein [20,21]. The natural split-site (C35) and engineered split-sit (C15) a e marked with
arrows [22]. The N-terminal split fragment of the natural split intein is colored in blue. IntN used in
this study is colored in blue or cyan. The region corresponding to the IntC fragment used in this study
is highlighted in green. (d) Protein ligation by PTS using a split intein. PTS ligates the N-terminal
fragment of a protein of interest (POIN) fused with the N-terminal split intein (IntN) and the C-terminal
fragment of POI (POIC) fused with the C-terminal split intein (IntC). PTS results in ligated POIN-POIC
and excised IntN and IntC. The figures were adapted from [5].
In this study, we prepared split-intein fusions with the human Fc domain produced in Brevibacillus
choshinensis, a gram-positive bacterium. Brevibacillus choshinensis has an excellent ability to produce
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many exogenous proteins extracellularly [23,24]. We tested in vitro protein ligation between the
Fc domain and different model proteins, including the cyanobacterial lectin scytovirin tin (SVN).
SVN has antiviral activity against a variety of human pathogens, including the HIV-1 and SARS viruses,
by binding to glycosylated viral surface proteins [25–28]. The lectin-Fc fusion might thus function as a
carbohydrate-targeting antibody, namely ‘lectibody’ (Figure 3) [29].
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2. Results
2.1. Strategy to Produce Fc Fusions In Vitro
We dissected the IgG format at two different sites within the hinge region (Figures 1d and 4a).
The hinge region can be divided into the upper, core, and lower hinges [1,30]. The Fc domain with and
without the core region was fused with the C-terminal fragment (IntC) of the naturally split DnaE intein
from Synechocystis species, strain PCC6803 (SspDnaEC16) (Figure 4b). We chose Npu/SspDnaE chimeric
intein for protein ligation because it has been used successfully in the ligation of many protein domains
in vitro, and has a higher tolerance of amino acids at the +2 position [21]. Naturally split SspDnaE and
NpuDnaE inteins have a 36-residue IntC fragment (Figure 2c) [21]. Therefore, we termed the split-site
of these inteins as C35 (excluding the start codon Met residue) [12]. However, we selected C15 as
the intein split site, and used the engineered pair of NpuDnaE∆C16/SspDnaEC16, because this pair has
worked better for some model proteins than the naturally split C35 pair of split inteins (Figure 2c) [22].
We hypothesized that the shorter 15-residue IntC would disturb less the folding of the Fc domain.
Three different IntC-Fc fusion proteins (IntC-Fc, IntC+1S-Fc, and IntC-CPPC-Fc) were constructed in
this study (Figure 4b).
2.2. Cloning and Protein Expression of IntC-Fc in Brevibacillus choshinensis
The Fc domain without the hinge-region has been produced in Escherichia coli [31–33]. We decided
to use the commercially available Brevibacillus expression system which is suitable for the secretory
production of heterologous proteins up to 3.7 g/L [34,35]. Following the protocol of the commercial
Brevibacillus expression system (TakaraBio), we cloned the gene of IntC-Fc fusion protein with or without
the core hinge into pNY326 and pNCM02 with the signal peptide of HWP from the kit (Figure 4b).
Brevibacillus choshinensis has a distinctive cell surface structure containing one surface protein layer
formed by HPD31 cell wall protein (HWP) under the regulation of five tandem promoters, named
P1–P5. While pNY326 use P5 promoter, pNCM02 is a high-copy-number plasmid harboring a strong
promoter, P2, and a modified Sec signal sequence for efficient secretory expression in B. choshinensis [35].
We then compared the protein expression of the Fc fusions in TM and 2SY media (Figure 4c and
Supplemental Figure S1). We found that the cells harboring the pNCM02-backbone vector secreted
IntC-Fc fusion with the core hinge more quickly in 2SY than the cells bearing pNY326 backbone vector
in TM and SY media (Supplemental Figure S1).
2.3. Production of IntC-Fc for Protein Trans-Splicing
For the production of IntC-Fc fusions for protein ligation, we chose three different constructs IntC-Fc
(AJNCM18P), IntC+1S-Fc (AJNCM20A), and IntC-CPPC-Fc (AJNCM21A) (Figure 4). We constructed
IntC-Fc with or without the core hinge. Additionally, we created a variant replacing Cys+1 with Ser+1
for the active site of the intein at the so-called +1 position [21]. We first optimized the culture media
and analyzed the time-course of the expression using AJNCM18P (IntC-Fc without the core hinge)
as a model protein. The presence of the IntC-Fc was detected in both TM and 2SY media after three
days, and no significant increase was observed after four days (Figure 4c). Based on these results,
three different IntC-Fc fusion proteins were expressed and secreted under the P2 promoter in a 4-mL
scale using TM medium and compared after four days (Figure 4d). All three fusion proteins were
successfully secreted into the culture medium. Whereas the control protein HWP with the molecular
weight of 118 kDa accumulated mostly in the supernatant fraction, IntC-Fc and IntC+1S-Fc were also
detected in the pellet fraction, suggesting incomplete secretion of the fusion proteins or incorrect
folding of the protein. In contrast, IntC-CPPC-Fc was mainly present in the supernatant fraction.
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Figure 4. Vector designs and protein production of IntC-Fc. (a) Primary structure of the hinge region
of human IgG. (b) Vector maps of three constructs (IntC-Fc, IntC+1S-Fc, and IntC-CPPC-Fc) in the
backbone of pNCM02 and pNY326 vector. (c) Optimization of the growth media. Production of IntC-Fc
was compared in TM and SY media. Lanes 2d, 3d, 4d indicate SDS-PAGE analysis of the culture
supernatant after 2 days, 3 days, and 4 days of protein expression, respectively. (d) Comparison of
protein production between IntC-Fc, IntC+1S-Fc, and IntC-CPPC-Fc by SDS-PAGE analysis. Lanes S
and P indicate supernatant and pellet fractions fr t e culture medium after four days of protein
expression, respectively. The control cell wall protei ) and IntC-Fc are marked with arrows.
2.4. Purification of IntC-Fc Fusions
We purified IntC-Fc fusions using an N-te minal hex histidine (His-tag) incorporated in IntC by
Immobilized Metal Chelate Affinity Chromatography (IMAC) ( igures 4b and 5). Th yields were
27 mg and 15 mg per liter of the culture medium for IntC+1S-Fc and IntC-CPPC-Fc, respectively.
These yields were calculated from pooled 4-mL cultures after three days of protein expression. It is
noteworthy that we were unable to scale up to over 50 mL, abolishing the protein secretion of interest
at a larger scale. After the first IMAC purification, we tested the binding of IntC-Fc fusions to the
Staphylococcal protein A column by affinity chromatography. All three IntC-Fc fusions bound to a protein
A sepharose column and could be eluted by acid elution as used for IgG purification, indicating that the
overexpressed Fc domain is capable of binding to the protein A column, despite the N-terminal fusion
of IntC; 35–49% of the total protein could be recovered after the protein A affinity chromatography
and subsequent dialysis. The molecular mass of IntC-CPPC-Fc produced from B. choshinensis was
confirmed (Supplemental Figure S2).
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2.5. Model Proteins for Protein Ligation with IntC-Fc
To test the protein ligation of the purified IntC-Fc fusions, we prepared the B1 domain of IgG
binding protein G (GB1) and yeast SMT3 protein (SUMO domain) as the N-terminal target proteins.
Both GB1 and SUMO domains were fused with an N-terminal His-tag and with the N-terminal split
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fragment (IntN) of NpuDnaE∆C16 intein (NpuDnaEN123) for PTS. Both model proteins were previously
prepared and tested for protein ligation with other model proteins [22]. H6-GB1-IntN (NpuDnaE∆C16)
and H6-SUMO-IntN (NpuDnaE∆C16) were independently produced in E.coli and purified by IMAC
using the N-terminal His-tag (Figure 5b).
2.6. Protein Ligation of IntC-CPPC-Fc by Protein Trans-Splicing
The individually purified N-terminal precursor proteins (H6-GB1-IntN and H6-SUMO-IntN) and
three Fc fusion proteins (IntC-Fc, IntC+1S-Fc, and IntC-CPPC-Fc) were tested for in vitro protein
ligation (Figure 5). The incubation of a reaction mixture of IntC-CPPC-Fc and H6-GB1-IntN did not
result in any ligated product (H6-GB1-CPPC-Fc) (Figure 5c). However, the same reaction mixture
in the presence of a reducing agent, 0.5 mM TCEP (tris(2-carboxyethyl)phosphine), produced the
ligated product H6-GB1-CPPC-Fc, together with the spliced-out intein fragment. Despite the slow
reaction, i.e., requiring over 20 h, the in vitro ligation of IntC-CPPC-Fc with GB1 was possible under
reducing conditions (Figure 5c). We also tested in vitro ligation using 5 mM DTT instead of TCEP,
yielding a slightly faster reaction (Figure 5d). The requirement of a reducing agent suggests that
disulfide bonds in the core hinge region might hinder the PTS reaction. Indeed, we observed the dimer
formation of the Fc domain without a reducing agent, which could be prevented by removing the
core hinge and Cys at the +1 position of IntC (Supplemental Figure S3). Next, we tested the SUMO
domain as another model protein for in vitro protein ligation. Similar to GB1, we could produce
H6-SUMO-CPPC-Fc in the presence of 0.5 mM TCEP (Figure 5e–g). In the case of H6-SUMO, we
observed some premature cleavage of H6-SUMO-IntN, as reported previously [22]. Since two precursor
proteins, i.e., H6-SUMO-IntN and IntC-CPPC-Fc, have the same migration in SDS-PAGE, we could
not estimate the reaction yield precisely (Figure 5e). However, the ligation with the SUMO domain
accumulated the ligated product more than the ligation with GB1. We believe that this was because
GB1 has an affinity to the Fc domain, thereby limiting its access to IntC-Fc for PTS.
2.7. The Influence of the Core Hinge on Protein Trans-Splicing
The core hinge in IntC-CPPC-Fc is more rigid due to two disulfide bonds, and could therefore
complicate the folding of the Fc domain during protein production [30]. To evaluate the effect of these
disulfide bridges on PTS, we tested in vitro protein ligation of IntC-Fc and IntC+1S-Fc, which lack the
core hinge (Figure 5f,g). IntC+1S-Fc is expected to produce Fc fusion without any cysteine in the hinge
region, while both IntC-CPPC-Fc and IntC-Fc result in an additional “CFN” sequence in the hinge region,
which could form an interchain disulfide bond (Figure 4). The reaction mixture of H6-SUMO-IntN and
IntC-Fc produced the ligated product H6-SUMO-Fc only in the presence of 0.5 mM TCEP, similar to
IntC-CPPC-Fc (Figure 5e,f). Premature cleavage of H6-SUMO-IntN was observed both with IntC-Fc and
IntC-CPPC-Fc, whereas the reaction of H6-SUMO-IntN and IntC+1S-Fc did not show any premature
cleavage of H6-SUMO-IntN. This observation is presumably because the hydroxyl group of serine is
less nucleophilic than the thiol group of cysteine. Despite the slow reaction, the reaction mixture of
H6-SUMO-IntN and IntC+1S-Fc produced the ligated product H6-SUMO-S-Fc fusion. We expected
that H6-SUMO-IntN and IntC+1S-Fc would produce the ligated product without any reducing agent,
because the mutation of Cys to Ser was introduced at the active site of the +1 position (Supplemental
Figure S3). However, IntC+1S-Fc still required a reducing agent, suggesting that other cysteine residues
in the intein, such as the first residue of NpuDnaE intein, need reducing conditions.
2.8. In Vitro Production of the Lectin Fusion Protein by Protein Trans-Splicing
Encouraged by the results from the model proteins, we attempted to create ‘lectibody’ by replacing
the antigen-binding domains of IgG with a small lectin by PTS (Figures 3 and 6). Lectins are a
group of proteins that recognize and bind carbohydrates with high specificity. Since there are
characteristic carbohydrates, for example, on the surfaces of pathogens and cancer cells, lectins are
promising candidates as neutralizing and drug-targeting agents [26,35]. For example, cyanobacterial
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lectin scytovirin (SVN) is an antiviral lectin from Scytonema varium that binds to high mannose
oligosaccharides on the surface of the human immunodeficiency virus (HIV) [27]. Bivalent structures
of the IgG format could increase the binding of lectin when it is fused with Fc. Additionally, the Fc
domain could improve the in vivo stability of a small lectin protein.
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Figure 6. A lectin fusion protein, ‘lectibody’ (a) Schematic drawing of the ligation of a lectin (SVN)
with a model protein (GB1) by PTS. (b) SDS-PAGE analysis of the protein ligation of SVN and GB1.
The first two lanes show separately prepared N- and C-precursor proteins (TRX-H6-SVN-IntN and
IntC-GB1). Lanes 3 and 4 show the ligation reaction immediately after the mixture and after 8 h of
incubation, respectively. Lane 5 and 6 indicate samples before and after the proteolytic digestion by
enterokinase (EK), respectively. Lanes 7 and 8 show samples before loading on a protein A sepharose
column and the elution fraction from the column, respectively. (c) [1H,15N]-HSQC spectrum of the
segmentally isotopic labeled [15N]-SVN-[14N]-GB. (d) Schematic drawing of the production of SVN-Fc
fusion by PTS. (e) SDS-PAGE analysis of the time-course of the ligation between TRX-H6-SVN-IntN
and IntC-CPPC-Fc by PTS.
We produced SVN as a fusion protein with thioredoxin (TRX) as previously reported,
but additionally fused it with IntN (NpuDnaE∆C16) [27]. The construct TRX-H6-SVN-IntN was
expressed in E. coli under T7 promoter and purified with a His-tag by IMAC (Figure 6a,b).
We expressed and purified the model protein GB1 with IntC, as previously reported [22,36]. The reaction
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mixture of TRX-H6-SVN-IntN and IntC-GB1 in the presence of 0.5 mM TCEP produced the ligated
product TRX-H6-SVN-GB1 after 8 h (Figure 6b). The ligated product was immediately subjected to
proteolytic digestion by enterokinase (EK) using an EK site engineered between the His-tag and SVN.
The proteolysis of TRX-H6-SVN-GB1 resulted in two proteins, TRX-H6 and SVN-GB1 (Figure 6a,b).
After digestion with EK, we removed the His-tagged TRX-H6 by affinity chromatography using
IgG sepharose (Figure 6b, lane 8). SVN contains ten cysteines which need to form five disulfide
bonds correctly, despite the presence of free cysteines of IntN. These disulfide bonds facilitate
SVN folding to the native conformation [27,28]. Since we had to use reducing conditions for PTS,
we prepared segmentally isotope-labeled SVN-GB1 for the structural assessment of SVN. We used
15N-labeled TRX-H6-SVN-IntN produced in 15N-labeled medium and unlabeled IntC-GB1, resulting
in segmentally labeled [15N]-SVN-[14N]-GB1 (Figure 6c) [36,37]. The molecular weight of the ligated
[15N]-SVN-[14N]-GB1 was also confirmed by mass-spectrometry (Supplemental Figure S4). The [1H,
15N]-HSQC spectra of SVN with invisible GB1 tag did not show well-dispersed peaks typical for the
well-folded globular domain, indicating that SVN was incorrectly folded or unfolded. The fusion with
IntN or the ligation in reducing conditions likely affected the correct folding of SVN. We assume that
the ligated SVN-GB1 prepared in this study was biologically inactive.
2.9. In vitro Production of a Lectibody by Protein Trans-Splicing
Despite the analysis of SVN-GB1, we tested IntC-CPPC-Fc and TRX-H6-SVN-IntN for protein
ligation in the presence of 0.5 mM TCEP (Figure 6d,e). As observed with SUMO-IntN, cleavage
reactions were apparent. The ligated product TRX-H6- SVN-CPPC-Fc accumulated after 3 h of reaction
(Figure 6e). This observation confirmed that it was feasible to produce ’lectibody’ in vitro by ligating
the Fc domain and a lectin using PTS, even though SVN bearing five disulfide bonds is not ideal for
PTS, which requires reducing conditions. Several algal lectins contain no or few disulfide bridges such
as griffithsin, which could be better candidates for ‘lectibody’ production by PTS [38].
3. Discussion
Inspired by heavy-chain antibodies from camelids composed of only two heavy chains, we
decided to create Fc fusion proteins in vitro at the N-terminus of the Fc region. In heavy-chain
antibodies, 50-kDa antigen-binding domains of IgG, which consist of VH, VL, CL, and CH1 domains, are
replaced with a smaller 12-kDa variable domain (VHH). We hypothesized that carbohydrate-binding
proteins like lectins could be able to replace the role of the variable domain of VHH as a binding
domain in IgG format when fused at the N-terminus of Fc domain (Figures 3 and 6d). Such Fc fusion
proteins might function like an antibody, i.e., ‘lectibody’, with a bivalent binding capability [29].
Previously, a lectibody was engineered as a genetic fusion of a lectin and Fc domain, and produced in
plants [29]. The production of full-length antibodies or antibody fragments in large quantities can be
challenging in bacterial overexpression systems because the disulfide bonds need to form correctly [39].
Mammalian expression systems have been established for the large-scale production of monoclonal
antibodies, but establishing a cell-line for each new monoclonal antibody or a fusion protein requires
time-consuming optimizations [40]. Additionally, protein production in mammalian cells can be more
expensive and slower compared with bacterial expression systems [39]. Heterogenous expression
using mammalian cells could also be more problematic than bacterial expression for engineered foreign
proteins from different organisms, such as from plants and bacteria, even in small quantities. Therefore,
we developed an in vitro protein ligation approach, which provides an alternative solution for the
production of Fc fusions. The in vitro protein ligation approach enabled us to produce various fusion
proteins using off-the-shelf domains that were preproduced in different suitable host organisms for
each domain. This off-the-shelf protein ligation approach avoids time-consuming steps to optimize the
expression and purification for each fusion protein. Once individual domains have been prepared and
stored, only the protein ligation step needs optimization.
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In this study, we demonstrated the feasibility of producing N-terminal fusion proteins of the
Fc domain in vitro by PTS. PTS successfully ligated the Fc domain made in Brevibacillus and other
domains produced in E. coli. The method worked for the Fc domain, both with and without the core
hinge region, although the reaction required reducing conditions. C-terminal fusions of a full-length
IgG and Fc domains by PTS have been demonstrated previously, resulting in functional IgGs with a
high ligation efficiency (80%) under reducing reaction conditions [41,42]. Reducing conditions had to
be employed in previous reports, as well as in this study. The reducing conditions affected neither
antibody affinity nor integrity by the protein ligation using PTS [41,42]. This observation indicated
that Fc-fusion proteins generated by PTS could be further exploited for various in vitro products
of Fc fusions, including bispecific antibodies, if two orthogonal split inteins could be used [42,43].
We successfully demonstrated the production of an Fc fusion of SVN, which is a model lectin bearing
five disulfide bridges, and the N-terminal split intein in E. coli, as previously reported [27,28]. However,
the SVN domain in the ligated product by PTS appeared to be unfolded or misfolded, as revealed by
NMR analysis using segmental isotopic labeling of SVN [36,37]. We believe that the folding problem
of SVN was due to the reducing condition used in the protein ligation reaction by PTS, and that the
ligated product was functionally inactive. We chose SVN from the cyanobacterium Scytonema varium
as a model system. SVN binds to various viruses, including HIV glycoproteins, SARS coronavirus, and
Ebola virus [28,38,44]. It might be possible to use the fusion protein of antiviral lectins as a therapeutic
anti-HIV or anti-SARS drugs as a lectibody. In our study, however, SVN bearing five disulfide bonds
turned out to be a nonideal candidate for in vitro protein ligation by PTS, at least with split DnaE inteins
that require reducing conditions for PTS. Many other lectins contain no disulfide bridges, such as
griffithsin from red algae, which also binds to gp120 and gp41 of HIV with high affinity, as well as to
SARS coronavirus [38,45,46]. These lectins bearing no disulfide bonds could be more easily developed
as lectibodies with therapeutic potential when the intein-Fc fusions are prepared from mammalian cells
for the effector functions of IgG, such as ADCC. As the Fc domain could improve the pharmacokinetic
properties, the Fc domain may be a good fusion partner for other binding domains [29].
We used the chimeric Npu/SspDnaE split intein with a cysteine residue at the +1 position, which is
required for protein splicing reactions and remains in the ligated product. We replaced the cysteine
with a serine residue at the +1 position in one of the IntC-Fc precursors (IntC+1S-Fc). This construct,
however, still requires reducing conditions for PTS reaction, despite the lack of cysteine in both the
intein and hinge regions. This result suggests that other cysteines, such as the first residue of the
intein, which is responsible for the first step of the splicing reaction, still require reducing conditions.
However, the produced Fc domain retained the capability of protein A binding, indicating the proper
three-dimensional structure of the Fc domain by preserving the protein A binding surface. The structure
was preserved presumably because two buried intramolecular disulfide bridges in Ig folds (CH2 and
CH3) were not influenced by a reducing agent such as 0.5 mM TCEP (Supplemental Figure S3). In the
case of the Fc domain with core hinge, the two disulfide-bridges (CPPC) in the core hinge probably
have to be reduced to avoid steric hindrance with the IntN fragment. Several inteins in nature contain
no cysteine residue within their sequence, including the +1 position [47]. These cysteine-free inteins
might be alternatively exploited for PTS.
4. Materials and Methods
4.1. Bacterial Strains and Growth Conditions
B. choshinensis strain HPD31-SP3 (Takara Bio, Shiga, Japan), and E. coli Rosetta-gami 2 (DE3) pLacI
(Merck, Kenilworth, NJ, US) and T7 Express (New England Biolabs, Ipswich, MA, US) were used for
protein expression. MT medium, MT supplemented with 1.6 mM MgCl2, and 2SY media were used for
culturing B. choshinensis [35]. E. coli was cultured in Luria-Bertani (LB) medium. B. choshinensis was
transformed by electroporation with a protocol adjusted from the previous report [48].
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4.2. Construction of Plasmids
For the N-terminal target proteins, an E.coli expression vector for H6-SUMO-IntN was
constructed by transferring the gene of IntN from pHYDuet36 [22] into pHYRSF53 vector [49]
(addgene #64696) using BamHI and HindIII restriction sites, resulting in pHYRSF53-36. The gene
encoding TRX-H6-SVN was amplified from pET(SVN) by PCR with two oligonucleotides, HK901:
5′-TACACCATGGGAAGCGATAAAATTATTCAC and HK900: 5′-TAGGATCCAC TACCACCTCCC
GCAGCCGC GTGACCCGC, followed by cloning into pHYRSF53-36 between NcoI and BamHI sites,
resulting in pAJRSF25A bearing the gene of TRX-H6-SVN-IntN (NpuDnaE∆C15).
Expression vectors of IntC-Fc fusions in B. choshinensis were cloned as follows. The gene encoding
the DnaE C-intein (IntC) from Synechocystis sp. (SspDnaEC16) was constructed as described previously
and transferred into the pBAD vector, resulting in pSABAD7PG [25]. The gene of Fc domain bearing
CH2 and CH3from human immunoglobulin G1 was amplified from the L1-Fc vector (addgene #15124)
and cloned into pSABAD7PG, resulting in pGVBAD049. The N-terminal hexahistidine tag followed by
a thrombin cleavage site introduced by cloning the gene into pRSF vector with PstI site introduced
by PCR using two oligonucleotides of GV065: 5′- CAGGTAGCCATCATCATCATCATCACAGCAGC
and GV066: 5′-CAGTATATCTCCTTATTAAAGTTAAACAAAATTATTTCTACAGG, resulting in
pGVRSF55-049#2. The lower hinge sequence of ‘PAPELLGG’ was introduced by PCR assembly using the
four oligonucleotides GV065, AJ001: 5′-CCAGCACCTGAACTCCTAGGGGGACCGTCAGTCTTCCTC,
J002: 5′-CCCTAGGAGTTCAGGTGCTGGGTTAAAACAGTTGGCGGCGATAG, and HK548: 5′-TAC
AAGCTTATTTACCCGGAGACAGGG, and cloned into pGVRSF55-049#2 and pNCM02 vector using
PstI-HindIII restriction sites, resulting in pAJRSF18A and pAJNCM18P, respectively for the expression
of IntC-Fc. For the production of IntC+1S-Fc in B. choshinensis, the vector pAJNCM18P was mutated by
inverse PCR using a pair of the two primers HK866: 5′- GGTGCTATCGCCGCGAATTCTTTTAACCC
AGCACCTG and HK867: 5′-CAGGTGCTGGGTTAAAAGAATTCGCGGCGATAGCACC, resulting in
pAJNCM20A. For IntC-CPPC-Fc, the core hinge ‘CPPC’ was introduced into pAJRSF18P by inverse PCR
using the two primers HK881: 5′-TTGCCCACCGTGCCCAGCACCTGAGCTCCTAGGGGGAC and
HK882: 5′-GGTGCTGGGCACGGTGGGSAATTAAAACAGTTGGCGGCG, resulting in pAJRSF21B.
The gene corresponding to IntC-CPPC-Fc was transferred from pAJRSF21B to pNCM02 or pNY326,
resulting in pAJNCM21A and pAJNY21F vectors with two different promoters. The pAJNCM18P,
pAJNCM20A, pAJNCM21A, pAJNY21F, pHYRSF53-36, and pAJRSF25A will be available from
Addgene (www.addgene.org) with addgene #153166, #153167, #153168, #153169, #153170,
and #153171, respectively.
4.3. Expression and Purification of Fc Fusions from B. choshinensis
The plasmids pAJNCM18P, pAJNCM20A, and pAJNCM21A were transformed into B. choshinensis
for protein expression and incubated in 4 mL of TM media at 30 ◦C, 200 min−1 overnight. The precultures
were then inoculated by a 100-fold dilution and incubated in 4 mL 2SY medium at 30 ◦C. After 3–4 days,
the culture supernatants were collected and subjected to SDS-PAGE analysis of the protein incubation.
The culture supernatants were collected, centrifuged (42,740× g, 50 min, 4 ◦C), and loaded onto a 5-mL
HisTrap FF column (GE Healthcare, Chicago, IL, USA). Unbound contaminants were washed off with
35 mM imidazole, and bound proteins were eluted with a 15- or 20-mL linear gradient of imidazole
(35 mM–250 mM) in 50 mM sodium phosphate, 300 mM NaCl, pH 8.0. Fractions were collected and
monitored by measuring absorbance at 280 nm (A280), and their purity was confirmed by SDS-PAGE.
The fractions containing target proteins were pooled and dialyzed overnight at 4 ◦C against 20 mM
sodium phosphate, pH 6.5 (protein A binding buffer) using 6–8 kDa molecular weight cut-off (MWCO)
membrane. The dialyzed samples were concentrated using a centrifugal filter device (Vivaspin 20, 3
kDa MWCO, GE Healthcare) and clarified by centrifugation (20,817× g, 15 min, 4 ◦C) prior to loading
on a 1-mL HiTrap Protein A HP column. After washing, the bound proteins were eluted with a 2-mL
linear gradient of 100 mM sodium citrate, pH 3.5 (0–100%). Fractions were collected and monitored
by measuring A280 and by SDS-PAGE examination. The fractions containing the target proteins were
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immediately neutralized with 20% (v/v) 1 M Tris, pH 9.5, pooled, and dialyzed overnight at 4 ◦C
against 10 mM Tris, 500 mM NaCl, 1 mM EDTA, pH 7 (ligation buffer). When necessary, the dialyzed
samples were concentrated using a centrifugal filter device (Microcon YM-10, 10kDa MWCO, Millipore,
Temecula, CA, US).
4.4. Expression and Purification of the N-Terminal Model Domains
Expression vectors pHYDuet36 [22], pHYRSF53-36, pAJRSF25A, and pSZRS7PG [22] were
transformed into E. coli Rosetta-gami 2(DE3)pLacI. A single transformant was grown overnight in
50 mL LB medium, at 30–37 ◦C, 220 min−1. The overnight culture was diluted into 2 L of LB medium
in three shake flasks and cultured at 37 ◦C, 220 min−1. When OD600 reached 0.5–0.6, protein expression
was induced with IPTG in the final concentration of 40 µg/mL. After 4-h protein expression, cells were
harvested by centrifugation (8,980× g, 10 min, 4 ◦C) and resuspended into 50 mM sodium phosphate,
300 mM NaCl, pH 8.0. The cell suspension was flash-frozen with liquid nitrogen and stored at −70 ◦C.
After thawing, cells were lysed by sonication. Cell debris was removed by centrifugation (42,740× g,
50 min, 4 ◦C), and the expressed proteins were further purified by polyhistidine tag IMAC with a linear
gradient of 50–250 mM imidazole. Elution from the HisTrap FF column was dialyzed overnight at 4 ◦C
against 10–20 mM Tris, 500 mM NaCl, 0–1 mM EDTA, pH 7–8 using 6–8 kDa MWCO membrane.
4.5. Protein Trans-Splicing Assays
For ligation reactions, equal amounts of the two precursor proteins were mixed at a final
concentration of 10–18 µM. The reactions were conducted using a bench-top shaker (Thermomixer
Comfort R, Eppendorf) at 25 ◦C with mild shaking (350 rpm) in either reducing or nonreducing
conditions. For reducing conditions, 0.5 mM TCEP and 5 mM DTT were tested. The reactions were
monitored periodically after mixing by reducing SDS-PAGE. Each sample for SDS-PAGE was mixed 1:1
with 2× SDS sample buffer containing 200 mM DTT and heated at 95 ◦C for 5 min to stop the reaction.
The samples were either loaded on a gel immediately or stored overnight at −20 ◦C.
SDS-PAGE and protein A affinity chromatography were used to analyze the effect of protein
trans-splicing reaction conditions on intramolecular disulfide bonds. Proteins AJNCM18P, AJNCM20A,
and AJNCM21A at a concentration of 15 µM were incubated in the presence of 0.5 mM TCEP or 5 mM
DTT at 25 ◦C, 350 rpm (Thermomixer Comfort R, Eppendorf, Hamburg, Germany). Control reactions
were incubated without a reducing agent. After 3 h, samples were mixed with the SDS sample buffer
and analyzed on a gel. AJNCM21A at a concentration of 14 µM was incubated in the presence of
0.5 mM TCEP for 1.5 h and stored overnight at 4 ◦C. The buffer was exchanged for a protein A binding
buffer in a centrifugal filter device (Amicon Ultra-4, 3-kDa MWCO, Millipore, Temecula, USA), and the
sample was loaded onto the protein A column.
5. Conclusions
We demonstrated an off-the-shelf approach to producing Fc fusion proteins at their N-terminus
by in vitro protein ligation using PTS. Independently prepared N-terminal domains made in E. coli
were ligated in vitro with the C-terminal Fc domain produced in Brevibacillus choshinensis. The in vitro
product could constitute an IgG-like Y-shape structure with bivalent binding sites. In nature, there are
many natural bioactive proteins, peptides, and domains like lectins that bind to various receptors and
ligands but which have not been widely used as a binding domain in IgG-like format. The production
of fusion proteins with such bioactive domains in vitro using an off-the-shelf approach paves a new
way for the rapid production of IgG-like molecules with known therapeutic potential without any
time-consuming genetic engineering and optimization. The off-the-shelf approach using premade
domains could be advantageous for drug development against rapidly emerging infectious diseases.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/11/
4011/s1.
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Abbreviations
VH variable heavy chain domain
VL variable light chain domain
VHH the variable domain of heavy chain-only Ab
mAb monoclonal antibody
BsAb bispecific antibody
scFv single-chain variable fragment
BiTE bispecific T-cell engager
TRX thioredoxin
NMR nuclear magnetic resonance
HSQC heteronuclear single quantum coherence
SVN scytovirin
Fc the Fc domain of Immunoglobulin G
GB1 the B1 domain of IgG binding protein G
PTS Protein trans-splicing
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